Japan’s CBD Industry Recieves First Investments From Publicly Listed Companies Following
AstraSana Japan Co., Ltd. has formed a capital and business alliance with Japan’s GSI Creos Corporation, bolstered by their investment. This partnership will enhance the wholesale distribution of CBD raw materials across Japan, leveraging the strengths of both companies.
Through this alliance, the AstraSana Group, headquartered in Switzerland, will establish a robust supply chain to deliver Swiss-made, high-quality CBD raw materials across Japan, with a mission is to ensure customers receive safe, reliable products of the highest standard.
Through this alliance, AstraSana Group (headquartered in Switzerland) will establish a stable supply chain to deliver Swiss-made, high-quality CBD raw materials nationwide in Japan. We aim to provide safe and reliable products to our customers.
By leveraging GSI Creos’ extensive resources and networks, AstraSana says it will offer even higher-quality services to customers. Based on this robust partnership, it will actively contribute to the growth and development of the CBD market through various approaches.
“At AstraSana Japan, we prioritize safety through third-party analyses, ensure the delivery of superior-quality products, and place customer trust and satisfaction at the heart of everything we do. We are dedicated to enhancing customers’ ‘Quality of Life’ (QOL) while staying at the forefront of technological innovation.
The Potential of CBD in the Japanese Market
CBD (Cannabidiol), a hemp-derived compound, is legally recognized as a safe material in Japan. With global demand on the rise, the opportunities for CBD in the Japanese market are rapidly expanding. This collaboration strengthens AstraSana’s supply chain, addressing past challenges, and further promotes the availability of safe and reliable CBD products across the country.
About GSI Creos Corporation
Website: Home | GSI Creos Corporation GSI Creos is an innovative trading company with nine domestic and 24 international bases. Operating globally in both “textiles” and “industrial products,” their business spans a diverse range, including textile raw materials, apparel, chemicals, hobby materials, machinery, semiconductor components, and nanotechnology. Guided by the purpose, “Creating quality of life for the next generation,” GSI Creos champions ESG management to tackle social challenges and promote human well-being.
About AstraSana Group / AstraSana Holding AG
Website: AstraSana Holding AG The AstraSana Group is a leading global company specializing in cannabinoid raw materials and medical cannabis. Headquartered in Zurich, Switzerland, AstraSana Holding AG operates through affiliates in the Czech Republic, the UK, and Japan. Collaborating with partners across Europe and South America, including Belgium, the group continues to expand its worldwide presence.
Yves Antoniazzi
Nyckelord
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Följ news aktuell GmbH
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press Release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals. Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024. No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States. Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's
Growth and innovation as cornerstones of a strong democracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Pressmeddelande
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press Release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds25.4.2025 12:05:00 CEST | Pressmeddelande
- Picture is available at AP - Los Angeles/DNA - Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
DYMO® LETRATAG 200B VINNER DET PRESTIGEFYLLDA PRISET ”BUSINESS PRODUCT OF THE YEAR” - STRUKTURERAR OCH ORGANISERAR VARDAGEN24.4.2025 16:44:06 CEST | Press Release
Amsterdam – vikten av organisering, effektivitet och produktivitet i både personliga och professionella sammanhang har aldrig varit större. Detta då allt fler använder smarta lösningar för att förenkla sin vardag. DYMO®, en ledande leverantör av innovativa etikett- och utskriftslösningar, ligger här i framkant. Som ett erkännande har DYMO LetraTag 200B belönats med EOPA Best Business Product Award, en utmärkelse som lyfter fram hur den förenklat organisering både hemma och på kontoret. "Trenden mot smart självorganisering fortsätter", berättar Liesbet De Soomer, Global Marketing Director på DYMO. "LetraTag 200B stödjer utveckligen genom att erbjuda en användarvänlig lösning, som gör märkningen snabb och enkel. Med det här verktyget kan användaren strukturera vardagskaoset och organisera tillvaron.” EOPA Best Business Product Award, som delas ut årligen, uppmärksammar produkter som sticker ut för sitt nytänkande, sin funktionalitet och sin användarvänlighet. LetraTag 200B:s utmärkelse b
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.
Besök vårt pressrum